ScholarIQanswers from OpenAlex

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy

PaperCitations, authors & open-access status

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy have?

ScholarIQcitation count

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy has 610 citations in the OpenAlex counts ScholarIQ stores.

When was Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy published?

ScholarIQyear

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy has 2022 year in the ScholarIQ index.

What is the open-access status of Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy?

ScholarIQoa status

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy has hybrid oa status in the ScholarIQ index.

What is the DOI of Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy?

ScholarIQdoi

The DOI for Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy is on the source record.

What is the PMID of Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy?

ScholarIQpmid

The PMID for Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy is on the source record.

What is the OpenAlex record for Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy?

ScholarIQopenalex

The OpenAlex for Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial